(July 29, 2014) OCRF-funded research published earlier this month provides the first proof of principle that epigenomic strategies efficiently target ovarian cancer stem cells, which are key for treatment resistance and the major factor in therapy failures. OCRF grantees Kenneth Nephew, PhD and Daniela Matei, MD are first and senior author of the paper, which was … Continued
(July 28, 2014) Research published last week in Behavioral Medicine suggests that most high-risk women (>75%) do not know their risk for ovarian cancer. Women with a documented deleterious mutation in BRCA1 or BRCA2 are at substantially elevated risk for ovarian cancer. To understand what percentage of women with high risk family histories know their … Continued
(July 21, 2014) According to research funded in part by OCRF, circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and metastasize to other organs. This new finding, supported in part by an OCRF Program Project Development Grant to Anil Sood, MD, … Continued
(July 8, 2014) Frequent mutations in the ARID1A gene have been previously discovered in ovarian endometrioid and clear-cell cancers. Now research supported by OCRF has provided direct evidence that it is an authentic tumor suppressor gene using a mouse model. OCRF Ann Schreiber Mentored Investigator grantee Bin Guan, PhD is first author, and OCRF Scientific … Continued
Q&A with John Weroha, MD, PhD 2014 Liz Tilberis Early Career Award Mayo Clinic Were you always in interested in science? By the time I was in high school I knew I wanted to have a career in biology, but I think my interest actually started earlier. When … Continued
(July 1, 2014) There is “little evidence” that the use of conventional fertility hormones used for ovarian stimulation in the treatment of infertility increases the long-term risk of breast and gynecological cancers, according to the results of a significant 30-year follow-up study. However, the extended use of clomiphene citrate was associated with a higher risk … Continued
(June 25, 2014) Research presented at the annual meeting of the American Society of Clinical Oncology earlier this month suggests that palliative care delivered at the time of cancer diagnosis improves survival. A randomized trial of palliative oncology care in 207 patients with advanced cancer and their caregivers showed that the risk of death at … Continued
(June 24, 2014) Earlier this month, researchers reported results of a Phase II trial which looked at efficacy and safety of a biweekly gemcitabine, carboplatin, and bevacizumab combination in patients with platinum-sensitive recurrent ovarian, peritoneal, or tubal cancer. The results, which were published online June 5, 2014 in the journal Gynecologic Oncology, showed that biweekly … Continued
On Monday, June 16, 2014, Dr. Douglas Levine of Memorial Sloan Kettering Cancer Center presented a free webinar focusing on research news that was presented at 2014’s medical meetings. In his hour-long presentation, he focused primarily on new ovarian cancer research that was presented at the American Society of Clinical Oncology’s annual meeting, which took … Continued
Promising new combination treatments for ovarian cancer Dr. Joyce Liu, MD, on behalf of researchers from the National Cancer Institute (NCI) and Dana Farber Cancer Institute (DFCI), presented striking results from a Phase II trial testing the combination of the PARP inhibitor olaparib and the anti-angiogenesis drug cediranib (which blocks tumors from creating new blood … Continued
Posted by Laura Koontz on June 5, 2014 The 50th Annual Conference of the American Society of Clinical Oncology, held May 30 – June 3 in Chicago, featured a number of promising and thought provoking studies on ovarian cancer. Below is a brief summary of the most notable studies from the meeting. In the coming weeks, we’ll also post … Continued
(June 4, 2014) In a study presented at the American Society of Clinical Oncology annual meeting last week, researchers found that the combination of olaparib and cediranib (Recentin) kept recurrent ovarian cancer from worsening for almost nine months longer than treatment with olaparib alone. For this study, 90 women with recurrent ovarian cancer that was … Continued
Get email updates about research news, action alerts, and ways to join the fight.
